Indole derivatives as factor Xa inhibitors

US6906084B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Marc Nazare · Idstein, DE
• Melanie Essrich · Frankfurt am Main, DE
• David William Will · Schwalbach, DE
• Hans Matter · Langenselbold, DE
• Kurt Ritter · Heidelberg, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE

Key dates

• Filing date: Nov 21, 2002
• Grant date: Jun 14, 2005
• Expiry date: Jan 8, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.